Haisco has also signed an agreement to be the exclusive distributor of Regentis Biomaterials' hydrogel, developed to treat cartilage damage, in China.

Regentis Biomaterials, an Israel-based company developing treatments for damaged cartilage, has closed a $15m series D round led by pharmaceutical company Haisco.

Haisco invested alongside Generali Investment, a subsidiary of insurance group Generali, as well as venture capital fund Medica Venture Partners, VC firm SCP Vitalife Partners and T³, the technology transfer office of Israeli university Technion.

Founded in 2004, Regentis has developed a hydrogel called GelrinC to regenerate tissue in order to treat articular cartilage lesions.

GelrinC, based on…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?